Detalhe da pesquisa
1.
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
J Biol Chem
; 295(3): 757-770, 2020 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822503
2.
The impact of phosphatases on proliferative and survival signaling in cancer.
Cell Mol Life Sci
; 75(15): 2695-2718, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29725697
3.
Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.
Proteomics
; 17(22)2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961369
4.
Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.
Proc Natl Acad Sci U S A
; 111(50): 17995-8000, 2014 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25453078
5.
Bisphosphonates inactivate human EGFRs to exert antitumor actions.
Proc Natl Acad Sci U S A
; 111(50): 17989-94, 2014 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25453081
6.
Reengineered tricyclic anti-cancer agents.
Bioorg Med Chem
; 23(19): 6528-34, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26372073
7.
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Nat Commun
; 14(1): 5253, 2023 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37644036
8.
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
Cancer Res
; 82(4): 721-733, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921012
9.
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.
J Clin Invest
; 118(8): 2711-21, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18596922
10.
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3ß-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Mol Cancer Ther
; 20(4): 676-690, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33568357
11.
Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].
Bioorg Med Chem
; 23(23): 7487, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28290285
12.
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
Oncogene
; 39(3): 703-717, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31541192
13.
The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
PLoS One
; 15(10): e0240169, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33027304
14.
Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.
Cancer Cell
; 38(1): 129-143.e7, 2020 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32531271
15.
Targeting PP2A in cancer: Combination therapies.
Biochim Biophys Acta Mol Cell Res
; 1866(1): 51-63, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30401535
16.
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
JCI Insight
; 4(4)2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830869
17.
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Cancer Res
; 79(16): 4242-4257, 2019 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142515
18.
Therapeutic targeting of PP2A.
Int J Biochem Cell Biol
; 96: 182-193, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29107183
19.
Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.
Mol Cancer Ther
; 17(11): 2481-2489, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30206106
20.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Sci Transl Med
; 10(450)2018 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30021885